![FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations](https://mma.prnewswire.com/media/2084187/Logo.jpg)
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
![Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis | Targeted Oncology Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis | Targeted Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-022-00868-z/MediaObjects/11523_2022_868_Fig1_HTML.png)
Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis | Targeted Oncology
![Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-019-0038-9/MediaObjects/41392_2019_38_Fig2_HTML.png)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy
![EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications - ScienceDirect EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204511701292-gr1.jpg)
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications - ScienceDirect
![Yüksel Ürün on X: "@US_FDA just approved a new first-line treatment for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. #NSCLC #LungCancer ⭕️Amivantamab-vmjw has been approved by the FDA Yüksel Ürün on X: "@US_FDA just approved a new first-line treatment for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. #NSCLC #LungCancer ⭕️Amivantamab-vmjw has been approved by the FDA](https://pbs.twimg.com/media/GHpzdg3XwAA_yxV.jpg:large)
Yüksel Ürün on X: "@US_FDA just approved a new first-line treatment for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. #NSCLC #LungCancer ⭕️Amivantamab-vmjw has been approved by the FDA
![Cancers | Free Full-Text | EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy Cancers | Free Full-Text | EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy](https://pub.mdpi-res.com/cancers/cancers-13-05132/article_deploy/html/images/cancers-13-05132-g001.png?1634281010)
Cancers | Free Full-Text | EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
![Poziotinib administered twice a day improves tolerability in NSCLC treatment with EGFR exon 20 insertion mutations - Onco Americas Poziotinib administered twice a day improves tolerability in NSCLC treatment with EGFR exon 20 insertion mutations - Onco Americas](https://www.oncoamericas.com/wp-content/uploads/2021/04/T11_Ret_EN.png)
Poziotinib administered twice a day improves tolerability in NSCLC treatment with EGFR exon 20 insertion mutations - Onco Americas
![Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases](https://www.frontiersin.org/files/Articles/733276/fonc-11-733276-HTML/image_m/fonc-11-733276-g001.jpg)
Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases
![Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases](https://www.frontiersin.org/files/Articles/733276/fonc-11-733276-HTML/image_m/fonc-11-733276-g003.jpg)
Frontiers | Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases
![Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-019-0038-9/MediaObjects/41392_2019_38_Fig3_HTML.png)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy
![Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology](https://onco-hema.healthbooktimes.org/article/36897-treatment-options-for-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations/attachment/93849.jpeg)
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
![EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives | Biomarker Research | Full Text EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives | Biomarker Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40364-022-00372-6/MediaObjects/40364_2022_372_Fig1_HTML.png)
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives | Biomarker Research | Full Text
![Current Oncology | Free Full-Text | Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Current Oncology | Free Full-Text | Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer](https://pub.mdpi-res.com/curroncol/curroncol-30-00515/article_deploy/html/images/curroncol-30-00515-g001.png?1690269004)
Current Oncology | Free Full-Text | Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
![Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article) | Published in International Journal of Cancer Care and Delivery Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article) | Published in International Journal of Cancer Care and Delivery](https://journal.binayfoundation.org/article/31316-molecularly-directed-therapy-of-advanced-metastatic-non-small-cell-lung-cancer-cme-article/attachment/79124.png)
Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article) | Published in International Journal of Cancer Care and Delivery
![Exon 20 insertion mutations induce de novo resistance to covalent and... | Download Scientific Diagram Exon 20 insertion mutations induce de novo resistance to covalent and... | Download Scientific Diagram](https://www.researchgate.net/publication/324704571/figure/fig1/AS:622567320731648@1525443024221/Exon-20-insertion-mutations-induce-de-novo-resistance-to-covalent-and-noncovalent-TKis.png)
Exon 20 insertion mutations induce de novo resistance to covalent and... | Download Scientific Diagram
![Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. | Semantic Scholar Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/34b09f5c795819c5c721feef901d0dfd71b3317b/3-Figure1-1.png)
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. | Semantic Scholar
![Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-019-0038-9/MediaObjects/41392_2019_38_Fig1_HTML.png)